ABIOMED Inc. (NASDAQ: ABMD) Upgraded by Baird to Outperform
Friday, April 29, 2022 12:20 PM

Related Stories



ABIOMED Inc. (NASDAQ: ABMD) was upgraded to Outperform from Neutral at RW Baird. The price target has been raised to $20 from $16.

The company reported third quarter fiscal 2011 revenue of $27.2 million, up 19 percent compared with the same period of fiscal 2010. GAAP net loss for the quarter was $800,000, or $0.02 per share, compared with  a GAAP net loss of $4.6 million, or $0.12 per share, for the third quarter of fiscal 2010. Cash, cash equivalents and short-term marketable securities totaled $59.2 million at December 31, 2021 compared with $54.1 million at September 30, 2010, representing an increase of $5.1 million.

Shares last traded at $16.55, up 0.06 percent on Thursday. ABMD has a 52-week low of $8.50 and a 52-week high of $17.38. The company has a total market cap of $630 million. The price to earnings ratio of the company is -0.010, and the PEG ratio is -0.010.

ABIOMED Inc., together with its subsidiaries, engages in the research, development, and sale of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery.  It sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, and internationally. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

 

Sponsors

Symbol :

Advertisement

Market news:

More news


Advertisement

    Recent Estimates

AnalystFirm NameSymbolEPS Estimate
ja teremtipTTG Investments GE$0.28
XXXXXXXXXX LVS$0.44
XXXXXXXXXX ISRG$2.49
XXXXXXXXXX AAPL$5.35
markinsurace guru CINF$0.36
XXXXXXXXXX AAPL$5.35
XXXXXXXXXX ISRG$2.49
JakeXXXXX PKD$0.06
XXXXXXXXXX CRTP$0.08
XXXXXXXXXX AA$0.27